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1,3-Galactosyltransferase 3Gal-T5 is highly expressed in the
colons of humans and certain primates due to a retroviral long ter-
minal repeat (LTR) acting as a strong promoter. Because this pro-
moter is inactive in other human tissues or mice, we attempted to
understandhowadoptionof a retrotransposonallowed the gene to
acquire tissue-specific expression. We identified three novel
5-UTRs of 3Gal-T5 mRNA, types A, B, and C, and found wide-
spreadexpressionof thetypeAtranscriptatmuchlower levels than
the LTR transcript, the expression of which is restricted to organs
of the gastrointestinal tract. Expression of the typeC 5-UTR tran-
script wasmostly restricted to the ileum,where it was expressed at
high levels.Weclonedthe5-flankingregionsofbothtypesAandB
5-UTRs, found deletion constructs functionally active as promot-
ers, and identified CCAAT-binding factor (CBF) and hepatocyte
nuclear factor 1 (HNF-1) as the principal nuclear factors control-
ling the promoters of types A and B 5-UTR transcripts, respec-
tively. The CCAAT-binding factor binding site and the entire
downstream sequence driving the expression of type A transcripts
in humans are structurally and functionally conserved in mice,
where theyconstitute aunique3Gal-T5promoter that appears to
be the ancestral promoter of the gene.TheHNF-1bindingmotif of
thesecondhumanpromoter is identical to theHNF-1/Cdxbinding
motif of the LTR promoter but is in the antisense orientation,
resulting in much lower binding affinity and promoter strength.
These data may explain the successful insertion of the transposon
during evolution.
1,3-Galactosyltransferase 5 (3Gal-T5)3 is a late-acting gly-
cosyltransferase responsible for the synthesis of type 1 chain
carbohydrates, including Lewis antigens, in human epithelial
cells (1, 2). 3Gal-T5 is highly expressed in human colon
mucosa, down-regulated in colon cancers (3), and large
amounts of its reaction products are found in the bile and small
intestine (4, 5). In some colon cancer cells, the first exon (exon
1) in the 5-UTRof the3Gal-T5 transcript is under the control
of a promoter located150 bp upstream and regulated primar-
ily by the transcription factors HNF-1 and Cdx (6). Interest-
ingly, the entire exon 1, as well as the HNF-1/Cdx binding
motif, belongs to a retroviral long terminal repeat (LTR)
sequence that is the dominant promoter for the 3Gal-T5 gene
in the colon but is inactive in other tissues where 3Gal-T5 is
expressed (7).
Transposable elements within eukaryotic genomes from
plants (8) to mammals (9) greatly affect gene expression both
at the protein (10) and regulatory sequence (11) levels. The
most common transposable elements in the human genome
are of retroviral origin (retroelements). Retroelements often
directly donate transcriptional regulatory signals that may
be either excluded from some genes or taken up by others.
The former group probably includes highly conserved genes
with basic functions, whereas the latter likely includes gene
classes that have recently expanded, such as those involved
in cellular responses to external stimuli (12). The glycosyla-
tion machinery includes gene products from both classes;
core enzymes probably belong to the former class (13),
whereas terminal glycosyltransferases to the latter (14). In
addition to 3Gal-T5, a retroviral LTR has been detected in
the 5-flanking region of two other glycosyltransferases, a
fucosyltransferase and a sialyltransferase (12), but little is
known about the promoter activity.
With respect to 3Gal-T5, the same investigators found an
alternative 5-UTR that is expressed in brain whose first exon,
exon3, is located100 kb upstream of the coding sequence
(7). This 5-UTR also contains two additional exons, 2 and
1, not present in the LTR-derived 5-UTR. More recently,
they also demonstrated that the 3Gal-T5 LTR promoter is
active in certain non-human primates but not in the mouse
genome, thus dating the transposon insertion to 25–30 mil-
lion years ago (15).
It is not clear whether the brain 5-UTR transcript is tissue-
specific, whether other 5-UTR promoters for the 3Gal-T5
gene exist in humans, whether the mouse ortholog of the gene
has one or more 5-UTRs, or whether the mouse ortholog
shares promoters with the human transcripts. Assuming that
the LTR sequence was active at the time of insertion (15),
understanding these aspects would allow us to understand the
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putative context of 3Gal-T5 expression at the time of LTR
insertion, which would thereby facilitate understanding of why
the insertion was tolerated and what stabilized the mobile ele-
ment. The present paper is aimed at identifying the native
3Gal-T5 promoter(s) present in the human genome, with par-
ticular attention to that (if any) common to the mouse genome
and to detect features in native promoter(s) that may explain
stabilization of the retroviral promoter. To address these issues,
we studied the 5-UTR of 3Gal-T5 transcripts through rapid
amplification of cDNA ends (RACE) analysis of RNA isolated
from different human sources and determined their relative
expression in various tissues and cell lines using competitive
reverse transcription (RT)-PCR. We then focused on the
5-flanking region of novel 5-UTR transcripts, trying to iden-
tify sequences active as promoters, using the luciferase reporter
assay and then binding sites for transcription factors through
electrophoreticmobility shift assay (EMSA).We also compared
the sequences of the novel 5-flanking regions with that flank-
ing themouse3Gal-T5 transcript, looking for possible homol-
ogies. Because we found a putative 3Gal-T5 promoter appar-
ently conserved in both species as well as a human sequence
poorly active as a promoter but able to bind the same transcrip-
tion factors as the LTR promoter, we studied such sequences in
detail. The results suggest that we found the ancestral mamma-
lian promoter of the gene as well as an apparently defective
promoter probably related to the successful insertion of the
transposable element in some primates.
EXPERIMENTAL PROCEDURES
Cell Lines, Tissues, and RNAs—Human breast cancer cell
lines MCF-7 and MDA-MB-231 (a gift of Dr. Fabio Dall’Olio,
University of Bologna, Italy) and the pancreas carcinoma cell
lineCapan-2 (AmericanTypeCultureCollectionHTB80)were
cultured in Dulbecco’s modified Eagle’s medium containing
10% fetal bovine serum, 100 units/ml penicillin, 1 mg/ml strep-
tomycin, and 2 mM L-glutamine. Human bile duct carcinoma
cells HuCC-T1 (Japanese Collection of Research Bioresources
0425) were cultured in RPMI 1640 medium containing the
same supplements as above. Human colon adenocarcinoma
cells Caco-2 and SW-1116 and human gastric carcinoma cells
MKN-45 were cultured as previously described (3, 16). Human
ileum and colon samples were collected at surgery and kindly
donated byDr. FilippoMare (Hospital di Circolo, Varese, Italy).
Total RNA from human tissues was obtained from Ambion
(mammary gland), Stratagene (colon, stomach, duodenum,
pancreas, mammary gland, thymus, and trachea), or Clontech
(stomach, pancreas, and mammary gland). Mouse total RNA
was purchased from Clontech. Total and poly(A) RNAs were
prepared from human tissues or cell lines as previously
reported (3, 16).
5-RACE—RNA ligase-mediated RACE was performed
essentially according to the manufacturer’s instructions with
the FirstChoice RLM RACE kit (Ambion). Each reaction, con-
taining RNase inhibitor, was treated with phenol/chloroform
and then mixed with 1 l of 20 mg/ml glycogen (Fermentas),
and the RNA was precipitated with sodium acetate/ethanol.
Five g of total RNA or 0.125 g of poly(A) RNA was used as
the starting material. A tobacco acid phosphatase reaction was
performed on one-half of the calf intestinal phosphatase-
treated RNA, and the whole amount was ligated to an RNA
adaptor. One-fourth of the obtainedmaterial was then used for
individual RTs in a final volume of 5.0 l using either avian
myeloblastosis virus orMoloneymurine leukemia virus reverse
transcriptase (GEHealthcare). Moloneymurine leukemia virus
RTswere incubated 20min at 37 °C, 40min at 42 °C, and 20min
at 45 °C. Avianmyeloblastosis virus RTswere incubated 40min
at 42 °C, 20 min at 45 °C, and 20 min at 50 °C. The coding
sequence-specific RT primer was 5-AGGAGGAAGAAT-
GTC-3, and the exon1-specific RT primer was 5-CTTAC-
TAGCCAATAAC-3. Amplifications (35 cycles) were per-
formed in 25 l of LA Taq (Takara) according to the
manufacturer’s recommendations, with 4 l of the RTs as the
template. Nested PCRs (30 cycles) were performed using 0.4–
2.0 l of the first amplifications and inner primers designed to
contain restriction sites. Amplified fragments were column-
cleaned, digestedwith appropriate restriction enzymes, gel-iso-
lated, and cloned into pGl3 vector for sequencing.
RT-PCR—Competitive RT-PCR was performed as previ-
ously described (3, 16). The human and mouse -actin and
human 3Gal-T5 coding sequence competitors and oligonu-
cleotide primers used were those previously described (3).
To quantify the different 3Gal-T5 5-UTRs, a competitor
was prepared by subcloning the entire sequence of the short
splicing variant of the type A 5-UTR in the HindIII-XhoI
sites of pCDM8 vector. Subsequently, a double-stranded oli-
gonucleotide (see below) with NdeI/HindIII ends was ligated
into the corresponding cohesive ends of the construct. The
oligonucleotide NdeI/HindIII ends are underlined; also
shown are primer sequences for exons 1C (bold) and 1B
(italic): 5-TATGAAGGGCATTGGAGACCCAGGGACC-
GCCTGCCCATTACAGTGACTCACA (upper strand) and
5-AGCTTGTGAGTCACGTAATGGGCATGGCGGTCC-
CTGGGTCTCCAATGCCCTTCA (lower strand). The
resultant construct was truncated by PdmI digestion and
self-ligated. The LTR competitor was prepared by PdmI
digestion and self-ligation of a plasmid with the LTR tran-
script cloned in the pCDM8 vector. Other exon-specific
upper strand primers were 5-CTGCCGGGGCTGCCCC-
GCGC (exon 1A), 5-CCTGCCCTTGGACATCAGAG-
CTGC (exon 1), and 5-CAAACCAGAGGTTCCTCTTAC-
CCAGC (exon 3); the lower strand primer for the coding
sequence was 5-GAATGGTGGGTACCTGTCCCACGG.
Mouse 3GalT5 cDNA was obtained by PCR and cloned in
the pCDM8 vector using an upper strand primer that
annealed to the mouse first exon (5-CGTCCCCTGCCCT-
GTCCCTTCTC) and a lower strand primer that annealed to
the end of the coding sequence (5-GGTCCTAGGTGCCC-
CCAGGGTCC). The upper strand primer for the mouse
ortholog of exon 3 was 5-GTGGGACCTCACTCACCG-
GCTGC.
Luciferase Assay—A cDNA encompassing the 5-flanking
region of 3Gal-T5 at positions 808 to 148 relative to the
beginning of exon 1A was amplified by PCR (30 cycles) using
LATaq andGC II buffer (Takara) following themanufacturer’s
recommendations. The 25-l reaction contained 150 ng of
human placenta genomic DNA as the template and primers
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having restriction sites at their 5-ends. The resultant fragment
was cloned in the corresponding sites of the vector pGl3 (Pro-
mega) upstream of the firefly luciferase coding sequence. Dele-
tion constructs were prepared by PCR (25 cycles) under similar
conditions with the proper primer pairs but using the plasmid
pGl3–808148 (5 ng/reaction) as the template. The 5-flank-
ing region of the mouse ortholog was prepared similarly using
corresponding primers. Site-directed mutagenesis of the
CCAAT-binding factor (CBF) sites was performed using Pfu
Turbo DNA polymerase (Stratagene) under the conditions
described in the QuikChange mutagenesis kit protocol. A
cDNA encompassing the 5-flanking region of 3Gal-T5 from
positions1011 to20 from the beginning of exon 1B as well
as the cognate deletion constructs were obtained and cloned in
pGl3 using the same approach but under standard LATaq reac-
tion conditions.
For transfection, host cells were plated 20 h in advance in
96-well plates with 50,000 cells/well in 0.1 ml of culture
medium. Transfection solutions were prepared by mixing
300 ng of test DNA with 15 ng of the Renilla luciferase
expression vector pRL-CMV (Promega) in 25 l of serum-
free medium and then adding 25 l of serum-free medium
containing 0.9 l of Lipofectamine (Invitrogen). Liposomes
were allowed to form 20 min at room temperature. Cells
were washed twice with serum-free medium, fed with trans-
fection solution, and incubated under regular growing con-
ditions for 3 h. After the addition of 0.1 ml of standard
medium, the incubation was continued for 20 h. The cells were
then washed with phosphate-buffered saline and lysed with 40
l of Passive Lysis buffer (Promega). The luciferase activity of
lysate aliquots was assayed using the dual luciferase reporter
system (Promega).
EMSA—EMSAs were performed with the Lightshift chemi-
luminescence kit (Pierce) following the manufacturer’s recom-
mendations, but the binding reaction volume was scaled down
to 10 l. In the case of G/C-rich sequences, the binding reac-
tions contained 50 mM KCl, 5.0% glycerol, 5.0 ng/l
poly(dIdC), and no detergent or MgCl2. Nuclear extracts were
prepared using the NE-PER extraction kit (Pierce), and 1 l of
extract (3–4g of protein) was added to each binding reaction.
Anti-HNF-1 (Santa Cruz Biotechnology catalog number
sc-8986X) or anti-CBF-B (catalog number sc-10779X), at 1
l/reaction, was incubated 30 min on ice in the binding reac-
tion before adding the probes. Competitor consensus
sequences for CBF (catalog number sc-2591), Ets-1 (sc-2549),
and Oct-1 (sc-2506) were double-stranded oligonucleotides
whose sequences corresponded to those suggested by Santa
Cruz Biotechnology, as indicated. HNF-1 competitor DNAwas
the 29-bp SIF3 sequence previously reported (17). DNA probes
were biotinylated using the biotin 3-end labeling Kit (Pierce).
DNA/protein complexes were separated by 5% native PAGE,
transferred to a nylon membrane, cross-linked under UV light,
and detected according to the kit protocol.
RESULTS
Identification of Different 5-UTRs in 3Gal-T5 Transcripts—
To identify novel 5-UTRs, we first performed 5-RACE analy-
sis using ileum RNA and an RT primer specific for the coding
sequence and found a single major band of650 bp. Sequenc-
ing of the cloned fragment revealed exon 3, exon 1, and a
novel exon of 92 bp, named exon 1C that was located 4 kb
upstream of exon1 in chromosome 21 (Fig. 1). RT-PCR anal-
ysis with an upper strand primer specific to this novel exon and
a lower strand primer localized in the coding sequence yielded
no amplification using either mammary gland or MKN-45 gas-
tric carcinoma cell RNAs. We could, however, successfully
amplify products in these reactions using an upper strand
primer specific to exon 1 and the same lower strand primer.
We then performed 5-RACE analysis starting from these same
RNAs using a primer that annealed to exon 1 for RT. We
obtained two major bands of 250 and 350 bp from mam-
mary gland RNA and two bands of 250 and 400 bp from
MKN-45 RNA. Sequencing of the fragments cloned from the
mammary gland revealed a short novel sequence of 23 bp (exon
1A) joined to exon1 and a longer one having the same 23-bp
sequence at the 5-end and an additional 108-bp sequence
(exon 2A) in between. In the genome, they indicate a transcrip-
tion start site located in a G/C-rich region33 kb from exon-1
(Fig. 1).
FIGURE 1. Genomic structure of the human 3Gal-T5 gene. The positions of the exons in the context of human chromosome 21 are shown following the
nucleotide (nt) numeration of the available sequence (GenBankTM accession number AF064860). The structure of three novel 5-UTRs of 3Gal-T5mRNAwith
their splice variants is presented together with the reported LTR-derived 5-UTR.
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Sequencing of the fragments cloned fromMKN-45 cells also
indicated the presence of exon 1A and, in addition, a novel
sequence of 200 bp (exon 1B) joined to exon 1, suggesting
another transcription start site located 16 kb upstream of
exon 1 (Fig. 1). RT-PCR performed with primers specific to
the novel exons and subsequent sequencing of the products
enabled us to delineate the exon structure of the 3Gal-T5
5-UTRs (Fig. 1). Type A 5-UTRs begin with exon 1A and
comprise two main splice variants, a longer one that includes
exon1 and a shorter onewithout it. A third veryminor typeA
variant that includes exon 2A is the longest and is almost unde-
tectable in competitive experiments. Type B and C 5-UTR
transcripts begin with exon 1B and 1C, respectively, and both
comprise the two main splice variants described above. Exon 3
is present at the 3-end of all of the novel 5-UTR-containing
transcripts, as is true for the LTR- and brain-derived 5-UTR
mRNAs (1, 7).
Distribution of 3Gal-T5 Transcripts with Different 5-UTRs
in Various Human Tissues and Cell Lines—We amplified
3Gal-T5 starting from normalized cDNA prepared from dif-
ferent sources using a common lower strand primer that
annealed to the coding sequence and different upper strand
primers specific to exons 1 (LTR), 1A, 1B, 1C,3, and 3. Ampli-
fication with the exon 3-specific primer yielded no products
regardless of the cDNA (data not shown). The LTR-derived
5-UTR mRNA predominated in the colon, duodenum, stom-
ach, and pancreas, where the actual expression levels ranged
from 0.3 to 10 fg/pg of -actin (Fig. 2). These tissues also con-
tained types A and B 5-UTR transcripts but at much lower
levels. On the other hand, type A 5-UTR transcripts were the
predominant 3Gal-T5 mRNA in the mammary gland, thy-
mus, and trachea, which lacked the LTR transcript. The actual
expression levels of type A transcripts in such tissues ranged
from 0.1 to 0.2 fg/pg of -actin, suggesting that they may be
under the control of a promoter weaker than the LTR pro-
moter. The type C 5-UTR-containingmRNApredominated in
the ileum (15 fg/pg of -actin) and was relevant in only one
other tissue, the colon. By contrast, type B 5-UTR transcripts
were not the major species in any of the normal tissues tested.
The actual expression levels of type B transcripts in any tissue
were0.15 fg/pg of -actin, suggesting that they may be under
the control of a very weak promoter. In some gastrointestinal
cancer cell lines, type B transcriptswere expressed at significant
levels, and in the case of SW-1116 (colon), Capan-2 (pancreas),
and HuCC-T1 (bile duct) cells, LTR transcript expression was
low or absent. Analysis of additional independent RNA samples
provided substantial sample-to-sample reproducibility; never-
theless, type C transcripts were present in one stomach and
colon sample but not in the other (Fig. 2, boxed panel). More-
over, the total amount of 3Gal-T5 transcript measured in the
sample pairs varied from 20 to 150% (Fig. 2), as previously
reported in human colon (3, 6).
Identification of Promoter Activity in the 5-Flanking Regions
of 3Gal-T5 Transcripts with Types A or B 5-UTRs—We
focused on types A and B 5-UTR transcripts because the tissue
distribution and expression levels made them candidates to be
under the control of native promoters.On the other side, no cell
line is currently available as amodel for further studies of typeC
transcripts. To identify such putative promoters, we cloned
800–1000-bp fragments of each 5-flanking region in the lucif-
erase reporter vector pGl3, prepared successive deletion
mutants, and studied their ability to drive luciferase expression
upon transfection into the appropriate cells. We used either
MKN-45 cells, which express the LTR, types A and B 5-UTR
transcripts, or as a control, MDA-MB-231 cells, which do not
express these transcripts. In the case of the 5-flanking region of
exon 1A (Fig. 3A), luciferase activity was evident when the
whole fragment was assayed in MKN-45 cells (808 to 20).
Inclusion of the intron sequence did not effect this activity
(808 to148), whereas cleavage of the first 47 bp upstreamof
the exon improved activity (223 to48). Activity was main-
FIGURE 2. Quantitative expression of different 3Gal-T5 5-UTR tran-
scripts in various human tissues and cell lines. RNA extracted from single
tissue samples and cell lines was reverse-transcribed, and normalized
amounts of the resultant first strand cDNAweremixedwith competitor (trun-
cated) cDNAs and subjected to PCR using primers specific to the following
3Gal-T5 exons: 3 (total transcript, Tot), 1A, 1B, 1C, and 1 (LTR). Twenty per-
cent of each amplification reaction was electrophoresed in a 1% agarose gel
and visualized by ethidium bromide staining. Three relevant examples are
shown in the upper panels. Target doublets are due to the splice variants
indicated in Fig. 1. Quantification was performed by densitometric scanning
of gel images. The amounts of amplified target cDNAs, presented in the bar
graphs, were calculated from their respective standard curves and normal-
ized to the amounts calculated for -actin. The boxed panel shows the more
relevant differences obtained analyzing independent RNA samples derived
from the corresponding tissues (marked with a caret). The results are the
means for two independent quantifications. Experimental variation was
always15% of the mean values.
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tained with fragment200 to48 (9-fold over background),
was drastically reduced with fragments175 to48 and150
to 48 (3.5-fold over background), and was lost with frag-
ment100 to48, suggesting that the sequences from200 to
175 and from 150 to 100 may contain binding sites for
relevant transcription factors. The highest luciferase activity
measured was 10-fold lower than that of the LTR promoter,
whereas the expression levels of type A transcripts in MKN-45
cells were only4-fold less than that of LTR transcripts (Fig. 2).
To further assess this aspect, we performed additional reporter
assays in MCF-7 cells, which mainly express type A 5-UTR
transcripts and no detectable LTR transcripts, as shown in Fig.
2. The luciferase activity driven by the LTRpromoterwas found
to be dramatically decreased in MCF-7 cells compared with
MKN-45 cells, but was still 11-fold higher than the back-
ground, whereas the activity of the 200 to 48 fragment
flanking the type A 5-UTR was maintained at 10-fold over
the background in these cells (Fig. 3B). These results suggest
that the LTR construct per se ismore highly active than the type
A promoter in reporter systems.
For the type B 5-UTR, the reporter activity of the whole
fragment (1011 to 20) was detectable but very low in
MKN-45 cells (Fig. 3C). Cleavage of the 3-end up to nucleotide
553 was found to be necessary to stimulate luciferase activity
(compare872 to20 and872 to313 with872 to553
and also 772 to 313 with 772 to 553), suggesting the
presence of an inhibitory region in this part of the sequence (see
last paragraph). However, the most active fragment (663 to
553) generated only4.5-fold higher luciferase activity than
the background, even though the expression levels of type B
5-UTR transcripts are similar to those of type A in MKN-45
cells. Fragments that included nucleotides up to 633 at the
5-end had activity, whereas those shorter did not, suggesting
that the sequence from633 to553may contain stimulatory
binding regions.
Characterization of the Promoter-driving Expression of Type
A 5-UTR Transcripts—To characterize the candidate pro-
moter of the type A 5-UTR transcripts, we prepared four over-
lapping DNA probes, each one 40 bp long, together repre-
senting the sequence from 215 to 102 from the
transcription initiation site. We used these probes in EMSAs
with nuclear extracts prepared from MKN-45 cells. A major
complex was found using probe 193 to 152, and other
minor complexes were evident with probes162 to127 and
140 to102 (Fig. 4A). Each complex appeared to be specific,
because it disappeared in the presence of molar excess of the
unlabeled probe. A search for potential transcription factor
binding sites in the193 to152 sequence using the TRANS-
FAC data base suggested high affinity sites for transcription
factors GATA-1 and Ets-1 and a lower affinity site for CBF. In
competition EMSAs with three substitution mutants of the
probe (Fig. 4B), one (m2), potentially affecting both GATA-1
andCBFbinding, failed to compete for complex formation. The
FIGURE 3.Promoter activity of the genomic sequences flanking exons 1A
and 1B. The indicated DNA fragments flanking exon 1A (A and B) or 1B (C)
were cloned in the pGl3 vector carrying the firefly luciferase gene and trans-
fected in MKN-45 cells that express all three types of transcripts (types A and
B both 1.5 fg/pg of -actin; LTR 5.9 fg/pg of -actin) or in MDA-MB-231 cells
that express no 3Gal-T5 transcripts together with a Renilla luciferase
reporter expression plasmid. Firefly luciferase activity was measured 24 h
later and expressed relative to the Renilla luciferase activity determined for
each sample. pGl3-basic, lacking any promoter sequence, and pGl3-control,
containing the SV-40 promoter, were used as negative and positive controls,
respectively. pGl3-LTR, having the sequence 148 to 28 flanking exon 1
and known as the LTR promoter, is shown for comparison. The constructs
representing the putative promoter sequence of type A 5-UTR transcripts
and its CBF site-directed mutant were also transfected in MCF-7 cells (B), a
mammary gland cell line expressing mainly type A 5-UTR transcripts (1.3
fg/pg of -actin) and no detectable LTR transcripts. The mutated CBF
sequence has CACGCGTCA instead of the wild type (wt) CACCTATCA. Values
are the means S.D. for at least two experiments in duplicate.
FIGURE4.Characterizationof thepromoterdriving typeA3Gal-T5 tran-
scripts. A, EMSAs were performed by incubating biotinylated oligonucleo-
tide probes with MKN-45 nuclear protein extracts in the presence of a 200-
fold molar excess of unlabeled oligonucleotides (competitor), and the
resultant complexes were separated by 5% native PAGE and visualized by
chemiluminescence. Oligonucleotide probe sequences are numbered from
the transcription initiation site (1). B, competitive EMSAs were performed
with probe 193 to 152 in the presence of mutated oligonucleotides or
consensus sequences of candidate transcription factors as competitors or
specific antibodies. Themutatedoligonucleotide sequences are shownat the
bottom.
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CBF competitor prevented complex formation, whereas com-
petitors with GATA or Ets family consensus sequences did not
affect the complex. In addition, preincubation of the binding
reactionwith an antibody specific to CBF yielded a supershifted
complex, indicating that CBF is involved in complex formation.
On this basis, we prepared a CBF site-directed mutant of the
pGl3–200-48 construct and found that the luciferase activity
measured upon transfection inMKN-45 orMCF-7 cells is dras-
tically reduced with respect to the wild type construct (Fig. 3B).
Altogether, the data confirm that the sequence is actually a
3Gal-T5 native promoter driving expression of the type A
5-UTR transcripts.
Comparison of the Human and Mouse 3Gal-T5 Genes—
The 5-UTR of the mouse 3Gal-T5 transcript is reported to
consist of two exons (GenBankTM accession number
NM_033149). The first one, rich in G/C, is at least 47 bp long
and may contain an additional 43 bp at the 5-end (15). The
second exon is 177 bp and appears homologous to the human
exon 3. By competitive RT-PCR, we found that the amount of
transcript originating at exon 1 corresponds to the total amount
of transcript expressed in mouse colon, stomach, and mam-
mary gland, suggesting that only one promoter is used inmouse
tissues (Fig. 5A). The relative expression level in the colon was
much higher than in the stomach or the mammary gland, as
found in human tissues, but the actual amount, relative to-ac-
tin, wasmuch lower than in the human colon.We compared 10
kb of mouse genomic sequence from chromosome 16 (18),5
kb upstream and 5 kb downstream from the transcription ini-
tiation, with the corresponding human sequences flanking the
three novel transcription initiation sites deduced from exons
1A, 1B, and 1C.No significant alignmentwas found in the latter
two cases, whereas a surprisingly high level of homology was
found between the mouse sequence and human sequence
flanking exon 1A,mostly in the region just upstreamof the exon
(Fig. 5B). In particular, the CBF binding site and the down-
stream sequence responsible for the other complexes detected
by EMSA, are almost completely conserved. To assess whether
they are functional, we cloned the sequence in the pGl3 vector
and transfected the construct inMKN-45 cells. Constructswith
mutated CBF sites were also transfected as controls. The lucif-
erase activities measured for the human and mouse sequences
were very similar and were similarly reduced by the CBFmuta-
tion (Fig. 5C). Moreover, in competitive EMSAs, the mouse
sequence containing the putative CBF site competed with the
corresponding human probe, and when used as a probe itself,
generated an identical complex that was competed out by the
human sequence, the CBF consensus sequence, or anti-CBF
(Fig. 5D). Similarly, the downstream sequence of the mouse
promoter prevented complex formation with the downstream
sequence of the human promoter. When labeled and used as a
FIGURE 5. Expression of3Gal-T5 inmouse tissues is under the control
of a promoter structurally and functionally similar to the human pro-
moter driving type A transcripts. A, quantitative expression of total (Tot)
3Gal-T5 transcript versus transcripts originating at exon 1 (1) was deter-
mined in three mouse tissues by competitive RT-PCR, as in Fig. 2. The
amounts of amplified target cDNAs, presented in the right panel, were
calculated from their respective standard curves and normalized to the
amounts calculated for -actin. B, ClustalW alignment of genomic regions
flanking human type A and mouse 3Gal-T5 transcription initiation sites.
Human chromosome 21 sequence from GenBankTM accession number
AF064860 (nucleotides 37,000–47,000) and mouse chromosome 16
sequence from GenBankTM accession number AC165170 (nucleotides
78,000–88,000) were used as input sequences. The first exons in the
5-UTRs are bold, and translation initiation sites (1) are shown in reverse
type (white on black background). The mouse-extended first exon is itali-
cized, the CBF binding site is boxed, and differences from the consensus
sequence are in lower case. C, the mouse genomic sequence homologous
to the human promoter of type A transcripts also contains a functional
CBF binding site. The indicated DNA fragments flanking mouse exon 1
were cloned in the pGl3 vector, transfected in MKN-45 cells, and luciferase
activity wasmeasured and expressed as in Fig. 3. Mutated CBF sequences for
both mouse and human have CACGCGTCA instead of the wild type (WT)
CACCTATCA. pGl3–200-48, containing the human promoter driving type A
transcripts, wasmutated identically and used as a control. pGl3-basic, lacking
any promoter sequence, is shown as a reference.D, competitive EMSAs were
performedwith humanprobe193 to152 in the presence ofmouse oligo-
nucleotide109 to67 and vice versa in the presence or absence of the CBF
consensus sequenceorGATAconsensus sequenceor anti-CBF. E, competitive
EMSAs were performed with human probe162 to127 in the presence of
mouse oligonucleotide91 to51 and vice versa.
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probe, the mouse sequence generated three complexes that
were apparently identical to the human complexes and whose
formation was prevented by a molar excess of the human
sequence (Fig. 5E). These data indicate that the promoter driv-
ing the mouse and the human type A transcripts is conserved
through evolution, suggesting that it is the ancestral 3Gal-T5
promoter.
Characterization of the Promoter Driving Expression of Type
B 5-UTR Transcripts—Because the type A promoter of
3Gal-T5 has no apparent features that can explain the inser-
tion and stabilization of the LTR promoter, we tried to charac-
terize the putative promoter region of the type B 5-UTR tran-
scripts of the gene, despite its low levels of activity in luciferase
reporter experiments. To this end, EMSAs were performed
using three overlapping DNA probes covering nucleotides
643 to500 from the origin of exon 1B. Amajor complex and
a very minor one were detected with probe614 to574 (Fig.
6A); both were inhibited by a molar excess of the probe and by
the shorter sequence 606 to 582 (Fig. 6B; WT, wild type).
Among six substitutionmutants of fragment606 to582,m5
failed to inhibit both complexes and m6 failed to inhibit the
minor one only (Fig. 6B). A TRANSFAC data base search using
both the parental and mutated sequences suggested the pres-
ence of recognition sites for transcription factors Oct-1 and
HNF-1. In competitive EMSAs (Fig. 6C), formation of themajor
complex was prevented by the addition of the HNF-1 binding
sequence of the SIF3 oligonucleotide as well as by an antibody
specific toHNF-1, indicating the presence of anHNF-1 binding
site, as reported for the LTR promoter (6, 7). To directly com-
pare these two promoters, competitive EMSAswere performed
using both sequences (Fig. 6D). The LTR sequence completely
abolished both the HNF-1 complex and the minor complex,
suggesting that the binding is due to a Cdx binding site (6).
Identical complexes were found with the LTR probe, but only
the major complex was inhibited by a 200-fold molar excess of
the 614 to 574 sequence, suggesting a lower affinity of the
614 to574 sequence for the minor complex. By varying the
competitor concentrations, we found that the relative affinity of
the614 to574 fragment for the HNF-1 site of SIF3 was also
much lower than that of the LTR sequence (Fig. 6E). A compar-
ison of these two sequences (Fig. 6F) further revealed a string of
nine identical nucleotides that includes the HNF-1 binding site
and the overlapping sequence suggested to be a Cdx binding
site (6). This same sequence is also present in the chimpanzee
ortholog located in chromosome 22 (19). In the SIF3 and
LTR sequences, the HNF-1/Cdx binding sequence is found
in the sense orientation, whereas in both the 614 to 572
fragment and in the chimpanzee ortholog, this element is
present in the antisense orientation. Taken together, our
present data support the hypothesis that the sequence rep-
resents the promoter for the type B 5-UTR transcripts, sug-
gesting that the low luciferase activity associated with this
fragment in our reporter experiments may be due to techni-
cal constraints probably related to the truncation of the 3-
region. To evaluate the possibility that this 3-region may
bind inhibitory factors, as suggested by luciferase experi-
ments, we prepared five overlapping DNA probes of40 bp
in length covering the sequence from494 to314 from the
transcription initiation site. EMSA performed with these
probes and nuclear extracts of MKN-45 cells provided many
specific spots, including a major complex with probe 353
to314 (Fig. 7A). The addition of a molar excess of the353
to330 fragment did not inhibit this complex efficiently but
only another minor complex formed with probe 353 to
314 (Fig. 7B). The major complex could be competed out
using fragment337 to314, and substitution mutations of
this fragment affected competition (Fig. 7B). The data indi-
cate that the 3-region of the putative type B promoter spe-
cifically binds putative regulatory factors in MKN-45 cells.
FIGURE6.Characterizationof thepromoterdriving typeB3Gal-T5 tran-
scripts and comparisonwith the LTR promoter. A, EMSAs were performed
as described in the legend to Fig. 4. B, competitive EMSAs were performed
with probe614 to574 in the presence of oligonucleotide606 to582
and its mutants. The bands at the top of the gel are unspecific. Mutated oli-
gonucleotide sequences are shownat thebottomof thepanel.C, competitive
EMSAswere performedwith probe614 to574 in the presence of consen-
sus sequences of candidate transcription factors or specific antibodies. SIF3 is
an HNF-1-binding oligonucleotide. D, competitive EMSAs were performed
with probe614 to574 in the presence of the LTR oligonucleotide or vice
versa. E, competitive EMSAs were performed with SIF3 as the probe in the
presence of different concentrations of oligonucleotides614 to574, SIF3,
or LTR. F, comparison of the SIF3 oligonucleotide sequence (antisense), the
corresponding sequence of the LTR (antisense), the corresponding sequence
of the 614 to 574 oligonucleotide (sense), and the corresponding
sequence of the chimpanzee ortholog (sense) (GenBankTM accessionnumber
AL954227, nucleotides 55926–55954). The HNF-1/Cdx binding motif of the
LTR sequence (see Ref. 6) is boxed.
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DISCUSSION
We find from our current data that multiple promoters are
present in the human3Gal-T5 gene. Our quantitative analysis
of the expression of four 5-UTR transcripts suggests that they
account for the large majority of the 3Gal-T5 mRNA mole-
cules expressed in the tissues that we studied. However,
because the total 3Gal-T5 mRNAs detected is not always
equal to the sum of the individual 5-UTR transcripts and also
because of inherent experimental error in these analyses, we
cannot rule out the possibility that additional 5-UTR tran-
scripts are present in some tissues driven by alternative cognate
promoters.
The LTR and type C promoters, both active in the gastroin-
testinal tract, appear as strong promoters; on the other side, the
ubiquitous type B promoter and the brain-specific promoter
appear to be very weak promoters, whose physiological rele-
vance is uncertain. The type A promoter, which is also quite
weak, is indeed responsible for 3Gal-T5 expression in various
tissues, such as the mammary gland, thymus, and trachea. This
type A promoter is mostly responsive to CBF stimulation and is
conserved in mouse, where it acts as a unique 3Gal-T5 pro-
moter. This ancestral promoter provides for low 3Gal-T5
expression (0.1–0.4 fg/pg of -actin) in both humans and mice
but has substantial gastrointestinal specificity in mice, as previ-
ously suggested (15). The intrinsicweakness of such a promoter
is explained by the relevant divergence from theCBF consensus
sequence. In fact, it has been reported that any variant of the
CCAAT core sequence, including CCTAT, strongly reduces
the binding affinity (20). These structural and functional fea-
tures are reflected inmodel cell systems, where luciferase activ-
ity driven by a type A promoter construct is much lower than
the SV-40 promoter control. A common role of 3Gal-T5 in
some general mammalian cell function may be proposed when
it is transcribed under the control of this promoter. Little infor-
mation is currently available concerning type 1 chain expres-
sion in the mouse (21, 22), where 1,4 fucosylation does not
occur (23). Moreover, it is not presently clear how 3Gal-T5
predominates in the mouse gastrointestinal tract, as it happens
in the human counterpart, simply using the conserved CBF-de-
pendent promoter.
On the other hand, the LTR promoter provides humans and
some primates with not only gastrointestinal tissue specificity
but also high expression levels (10 fg/pg of -actin in the
colon). In the human ileum, however, high expression levels
and possibly specificity is determined by another promoter not
yet characterized, leading to the proposal of a distinct role for
3Gal-T5 in intestinal cell-specific functions (6). The intrinsic
strength of the LTR promoter is also consistent with the con-
served andproper orientation of both theHNF-1 andCdxbind-
ing sites (6, 24) and is recapitulated by our in vitro experiments
showing very high luciferase activity for the LTR reporter con-
struct in model cells. However, nothing is currently apparent
with regards to the ancestral type A promoter that can explain
the insertion and stabilization of the LTR retrotransposon. On
this basis, we attempted to characterize the putative type B
promoter, even though it has activity in certain human gastro-
intestinal cell lines but has only very weak activity in the normal
tissueswe tested.We found that the luciferase activity driven by
the type B promoter construct was lower than expected in
MKN-45 cells, as they express typesA andB5-UTR transcripts
at equivalent levels. However, to measure luciferase activity, it
was necessary to remove a 552-bp segment from the 3-end of
the sequence, and this caused the possible deletion of specific
binding sites for inhibitory factors. In fact, we found that this
region binds various potential regulatory factors in MKN-45
cells. We speculate also that this truncation physically affects
the ability of the promoter to drive luciferase activity in vitro.
Moreover, additional binding sites for stimulatory factors may
also have been present in this deleted region, affecting the activ-
ity measured for the type B reporter construct. Continuing on
from these hypotheses, we pursued the characterization of the
type B putative promoter and did find that this promoter and
the LTR promoter share an almost identical HNF-1/Cdx bind-
ingmotif but placed in the opposite orientation. Because such a
perfect sequence match probably helped stabilize the element
at the time of its transposition, a suggestive hypothesis is that
the isolated sequence represents a remnant of a true native
promoter that was relevant at the time of the LTR insertion but
has since been overwhelmed by the mobile element. The pres-
ent disposition of binding sites for stimulatory and inhibitory
factors may not allow for full expression of the promoter in a
reporter system.
Because other human (but not mouse) genes have been
reported to have an LTR with or without similar expression
patterns (12), it will be interesting to verify whether the context
of the LTR insertion in these cases mirrors that here proposed
for the 3Gal-T5 gene.
We also found that the LTR transcript is poorly expressed or
not expressed at all in some gastrointestinal cancer cell lines. In
FIGURE 7. Binding of putative regulatory factors to the 3-region of the
typeBpromoter.A, EMSAswereperformedas in Fig. 4.B, competitive EMSAs
wereperformedwithprobe353 to314 in thepresenceof oligonucleotide
353 to 330 or oligonucleotide 337 to 314 and its mutants. Mutated
oligonucleotide sequences are shown at the left of the panel.
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some of these lines, the type B 5-UTR transcript is very detect-
able, indicating that its promoter, with an antisense HNF-1/
Cdx motif, is active to some extent. Given the dependence of
the two promoters on the same transcription factors (but the
higher affinity and strength of the LTR promoter), we hypoth-
esize that an unknown strong inhibitory mechanism specifi-
cally affects the LTR promoter in cancer cells. This is in good
agreement with the finding that the negative regulation of
3Gal-T5 in colon cancers (3, 6) exceeds the simple reduction
ofHNF-1 andCdx binding (6) and represents another source of
regulatory variations potentially introduced by retroelements.
Using exon 3-specific primer, we were unable to detect
3Gal-T5 by PCR in any cDNA we tested, suggesting that
such exon belongs to a brain-specific transcript placed under
the control of a distinct promoter yet unknown. Because the
expression levels of 3Gal-T5 in brain are extremely low (7),
such promoter is presumably very weak. In fact, other 1,3-
galactosyltransferases, such as 3Gal-T1 (25–27) and
3Gal-T2 (28), are expected to play a major role in tissues
and cells of neuroectodermal origin. In conclusion, the strict
conservation of the ancestral promoter from mice to
humans, together with the adoption of multiple promoters,
including the strong LTR promoter during evolution, sug-
gest that more work is needed to understand the contribu-
tion of 3Gal-T5 and its reaction products in specific cell
functions.
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